Ionis Pharmaceuticals, Inc. Increase (Decrease) in Contract with Customer, Liability
Ionis Pharmaceuticals, Inc. (IONS) reported Increase (Decrease) in Contract with Customer, Liability of -$28.89 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInContractWithCustomerLiability · last filed 2026-07-29
- Ionis Pharmaceuticals, Inc. increase (decrease) in contract with customer, liability for the quarter ending 2026-06-30 was -$8.08M.
- Ionis Pharmaceuticals, Inc. increase (decrease) in contract with customer, liability for the quarter ending 2026-03-31 was -$20.82M.
- Ionis Pharmaceuticals, Inc. increase (decrease) in contract with customer, liability for the quarter ending 2025-12-31 was -$19.13M.
- Ionis Pharmaceuticals, Inc. increase (decrease) in contract with customer, liability for the quarter ending 2025-09-30 was -$16.11M.
- Ionis Pharmaceuticals, Inc. increase (decrease) in contract with customer, liability for fiscal 2025 was -$69.73M.
- Ionis Pharmaceuticals, Inc. increase (decrease) in contract with customer, liability for fiscal 2024 was -$156.82M, a 1222.78% decline from fiscal 2023.
- Ionis Pharmaceuticals, Inc. increase (decrease) in contract with customer, liability for fiscal 2023 was $13.97M.
- Ionis Pharmaceuticals, Inc. increase (decrease) in contract with customer, liability for fiscal 2022 was -$71.25M.
| Period end | Increase (Decrease) in Contract with Customer, Liability 3 month | Increase (Decrease) in Contract with Customer, Liability 6 month | Increase (Decrease) in Contract with Customer, Liability 9 month | Increase (Decrease) in Contract with Customer, Liability 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$8.08M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-29 | -$28.89M 10-Q · filed 2026-07-29 | -$48.02M derived: sum of 3 quarters · filed 2026-07-29 | -$64.14M derived: sum of 4 quarters · filed 2026-07-29 |
| 2026-03-31 | -$20.82M 10-Q · filed 2026-04-29 | -$39.95M derived: sum of 2 quarters · filed 2026-04-29 | -$56.06M derived: sum of 3 quarters · filed 2026-04-29 | -$76.83M derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-12-31 | -$19.13M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$35.24M derived: sum of 2 quarters · filed 2026-02-26 | -$56.01M derived: sum of 3 quarters · filed 2026-07-29 | -$69.73M 10-K · filed 2026-02-26 |
| 2025-09-30 | -$16.11M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-29 | -$36.88M derived: sum of 2 quarters · filed 2026-07-29 | -$50.60M 10-Q · filed 2025-10-29 | -$64.90M derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-06-30 | -$20.77M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-29 | -$34.49M 10-Q · filed 2026-07-29 | -$48.79M derived: sum of 3 quarters · filed 2026-07-29 | -$81.76M derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-03-31 | -$13.72M 10-Q · filed 2026-04-29 | -$28.02M derived: sum of 2 quarters · filed 2026-04-29 | -$60.99M derived: sum of 3 quarters · filed 2026-04-29 | -$123.72M derived: sum of 4 quarters · filed 2026-04-29 |
| 2024-12-31 | -$14.30M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$47.27M derived: sum of 2 quarters · filed 2026-02-26 | -$110.00M derived: sum of 3 quarters · filed 2026-02-26 | -$156.82M 10-K · filed 2026-02-26 |
| 2024-09-30 | -$32.97M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-29 | -$95.70M derived: sum of 2 quarters · filed 2025-10-29 | -$142.52M 10-Q · filed 2025-10-29 | -$204.30M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | -$62.73M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-30 | -$109.55M 10-Q · filed 2025-07-30 | -$171.33M derived: sum of 3 quarters · filed 2026-02-26 | -$67.88M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | -$46.82M 10-Q · filed 2025-04-30 | -$108.60M derived: sum of 2 quarters · filed 2026-02-26 | -$5.16M derived: sum of 3 quarters · filed 2026-02-26 | -$19.81M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | -$61.78M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $41.66M derived: sum of 2 quarters · filed 2026-02-26 | $27.00M derived: sum of 3 quarters · filed 2026-02-26 | $13.97M 10-K · filed 2026-02-26 |
| 2023-09-30 | $103.45M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $88.79M derived: sum of 2 quarters · filed 2024-11-06 | $75.75M 10-Q · filed 2024-11-06 | $59.93M derived: sum of 4 quarters · filed 2025-02-19 |
| 2023-06-30 | -$14.66M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | -$27.70M 10-Q · filed 2024-08-01 | -$43.52M derived: sum of 3 quarters · filed 2025-02-19 | -$57.94M derived: sum of 4 quarters · filed 2025-02-19 |
| 2023-03-31 | -$13.04M 10-Q · filed 2024-05-07 | -$28.86M derived: sum of 2 quarters · filed 2025-02-19 | -$43.28M derived: sum of 3 quarters · filed 2025-02-19 | -$59.27M derived: sum of 4 quarters · filed 2025-02-19 |
| 2022-12-31 | -$15.82M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-19 | -$30.24M derived: sum of 2 quarters · filed 2025-02-19 | -$46.23M derived: sum of 3 quarters · filed 2025-02-19 | -$71.25M 10-K · filed 2025-02-19 |
| 2022-09-30 | -$14.42M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | -$30.41M derived: sum of 2 quarters · filed 2023-11-02 | -$55.43M 10-Q · filed 2023-11-02 | -$66.64M derived: sum of 4 quarters · filed 2024-02-21 |
| 2022-06-30 | -$15.99M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | -$41.00M 10-Q · filed 2023-08-09 | -$52.22M derived: sum of 3 quarters · filed 2024-02-21 | -$73.36M derived: sum of 4 quarters · filed 2024-02-21 |
| 2022-03-31 | -$25.02M 10-Q · filed 2023-05-03 | -$36.24M derived: sum of 2 quarters · filed 2024-02-21 | -$57.37M derived: sum of 3 quarters · filed 2024-02-21 | -$84.13M derived: sum of 4 quarters · filed 2024-02-21 |
| 2021-12-31 | -$11.22M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-21 | -$32.35M derived: sum of 2 quarters · filed 2024-02-21 | -$59.11M derived: sum of 3 quarters · filed 2024-02-21 | -$82.83M 10-K · filed 2024-02-21 |
| 2021-09-30 | -$21.13M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | -$47.89M derived: sum of 2 quarters · filed 2022-11-09 | -$71.61M 10-Q · filed 2022-11-09 | -$73.55M derived: sum of 4 quarters · filed 2023-02-22 |
| 2021-06-30 | -$26.76M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | -$50.48M 10-Q · filed 2022-08-09 | -$52.42M derived: sum of 3 quarters · filed 2023-02-22 | -$67.03M derived: sum of 4 quarters · filed 2023-02-22 |
| 2021-03-31 | -$23.72M 10-Q · filed 2022-05-04 | -$25.66M derived: sum of 2 quarters · filed 2023-02-22 | -$40.27M derived: sum of 3 quarters · filed 2023-02-22 | -$79.95M derived: sum of 4 quarters · filed 2023-02-22 |
| 2020-12-31 | -$1.94M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-22 | -$16.55M derived: sum of 2 quarters · filed 2023-02-22 | -$56.23M derived: sum of 3 quarters · filed 2023-02-22 | -$75.91M 10-K · filed 2023-02-22 |
| 2020-09-30 | -$14.62M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | -$54.29M derived: sum of 2 quarters · filed 2021-11-03 | -$73.97M 10-Q · filed 2021-11-03 | -$96.22M derived: sum of 4 quarters · filed 2022-02-25 |
| 2020-06-30 | -$39.68M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-04 | -$59.35M 10-Q · filed 2021-08-04 | -$81.61M derived: sum of 3 quarters · filed 2022-02-25 | -$105.00M derived: sum of 4 quarters · filed 2022-02-25 |
| 2020-03-31 | -$19.68M 10-Q · filed 2021-05-05 | -$41.93M derived: sum of 2 quarters · filed 2022-02-25 | -$65.32M derived: sum of 3 quarters · filed 2022-02-25 | -$98.61M derived: sum of 4 quarters · filed 2022-02-25 |
| 2019-12-31 | -$22.25M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-25 | -$45.64M derived: sum of 2 quarters · filed 2022-02-25 | -$78.93M derived: sum of 3 quarters · filed 2022-02-25 | -$119.28M 10-K · filed 2022-02-25 |
| 2019-09-30 | -$23.39M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-04 | -$56.68M derived: sum of 2 quarters · filed 2020-11-04 | -$97.03M 10-Q · filed 2020-11-04 | -$49.94M derived: sum of 4 quarters · filed 2021-02-24 |
| 2019-06-30 | -$33.29M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-05 | -$73.64M 10-Q · filed 2020-08-05 | -$26.56M derived: sum of 3 quarters · filed 2021-02-24 | -$63.20M derived: sum of 4 quarters · filed 2021-02-24 |
| 2019-03-31 | -$40.35M 10-Q · filed 2020-05-06 | $6.73M derived: sum of 2 quarters · filed 2021-02-24 | -$29.91M derived: sum of 3 quarters · filed 2021-02-24 | $481.69M derived: sum of 4 quarters · filed 2021-02-24 |
| 2018-12-31 | $47.09M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-24 | $10.44M derived: sum of 2 quarters · filed 2021-02-24 | $522.04M derived: sum of 3 quarters · filed 2021-02-24 | $494.25M 10-K · filed 2021-02-24 |
| 2018-09-30 | -$36.65M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-06 | $474.96M derived: sum of 2 quarters · filed 2019-11-06 | $447.17M 10-Q · filed 2019-11-06 | $446.28M derived: sum of 4 quarters · filed 2020-03-02 |
| 2018-06-30 | $511.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | $483.81M 10-Q · filed 2019-08-08 | $482.93M derived: sum of 3 quarters · filed 2020-03-02 | $458.41M derived: sum of 4 quarters · filed 2020-03-02 |
| 2018-03-31 | -$27.79M 10-Q · filed 2019-05-09 | -$28.68M derived: sum of 2 quarters · filed 2020-03-02 | -$53.19M derived: sum of 3 quarters · filed 2020-03-02 | |
| 2017-12-31 | -$889.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02 | -$25.41M derived: sum of 2 quarters · filed 2020-03-02 | $30.18M 10-K · filed 2020-03-02 | |
| 2017-09-30 | -$24.52M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-06 | $31.07M 10-Q · filed 2018-11-06 | ||
| 2017-06-30 | $55.59M 10-Q · filed 2018-08-07 | |||
| 2016-12-31 | -$85.31M 10-K · filed 2019-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |